



IFW

PTO/SB/21 (08-03)

Approved for use through 08/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10799,941	
	Filing Date	03/11/2004	
	First Named Inventor	Martha G. Welch	
	Art Unit	1615	
	Examiner Name	to be assigned	
Total Number of Pages in This Submission	25	Attorney Docket Number	5199-134

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 86 references
Remarks Form PTO/SB/08B and duplicate (22 pages) Information Disclosure Statement (2 pages) 86 references Return Postcard		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Todd Holmbo, Reg. No. 42,665	
Signature		
Date	07/06/2005	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Debbie Jenkins	
Signature		Date 07/06/2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Martha G. Welch *et al* Docket No.: 5199-134
Serial No.: 10/799,941 Examiner: to be assigned
Filed: March 11, 2004 Group Art Unit: 1615
Title: NOVEL MULTYPEPTIDE REGIMENT FOR THE TREATMENT OF AUTISTIC
SPECTRUM, BEHAVIORAL, EMOTIONAL AND VISCERAL INFLAMMATION/
AUTOIMMUNE DISORDERS

July 6, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(c)

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant hereby notifies the U.S. Patent and Trademark Office of the following documents, which are listed on the attached PTO/SB/08B form. The examiner may deem these documents to be relevant to patentability of the claims of the above-identified application. The submission of the listed documents is not intended as an admission that any of the documents constitute prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.


Applicants respectfully request that the listed documents be considered by the examiner and be made of record in the present application and that initialed a copy of form PTO/SB/08B be returned in accordance with MPEP §609.

It is understood that no fee is necessary for submission of this Information Disclosure Statement, because it is being filed before the later of three months from the filing date or the mailing of the first Office Action on the merits.

The Commissioner is hereby authorized to charge payment of any fees associated with this application or credit any overpayment to Deposit Account No. 02-4270.



Respectfully submitted,



Todd Holmbo
Reg. No. 42,665
Attorney for Applicants
BROWN RAYSMAN MILLSTEIN
FELDER & STEINER LLP
163 Madison Avenue
P.O. Box 1989
Morristown, New Jersey 07962-1989
Telephone No. 973.775.8930
Facsimile No. 973.775.8901

BRMFS1 599469v1



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/799,941
Filing Date	03/11/2004
First Named Inventor	Martha G. Welch
Art Unit	1615
Examiner Name	
Attorney Docket Number	5199-134

Sheet 1 of 11

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology. 2003 Apr;124(4)	
	2	Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med. 2003;35(1):2-11	
	3	Armando I, Carranza A, Nishimura Y, Hoe KL, Barontini M, Terron JA, Falcon-Neri A, Ito T, Juorio AV, Saavedra JM. (2001) Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation stress. Endocrinology. Sep;142(9):3880-9	
	4	Asarian L, Yousefzadeh E, Silverman AJ, Silver R. Stimuli from conspecifics influence brain mast cell population in male rats. Horm Behav. 2002 Aug;42(1):1-12. (not available - License restricted)	
	5	Aylward EH, Minshew NJ, Goldstein G, Honeycutt NA, Augustine AM, Yates KO, Barta PE, Pearson GD. MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults. Neurology. 1999 Dec 10; 53(9): 2145-50	
	6	Baker H, Joh TH, Ruggiero DA, Reis DJ. Variations in number of dopamine neurons and tyrosine hydroxylase activity in hypothalamus of two mouse strains. J Neurosci. 1983 Apr;3(4):832-43	
	7	Baron-Cohen S, Ring HA, Wheelwright S, Bullmore ET, Brammer MJ, Simmons A, Williams SC. Social intelligence in the normal and autistic brain: an fMRI study. Eur J Neurosci. 1999 Jun; 11(6):1891-8	
	8	Bauman M, Kemper TL. Histoanatomic observations of the brain in early infantile autism. Neurology. 1985 Jun; 35(6): 866-74	
	9	Bauminger N, Kasari C. Loneliness and friendship in high-functioning children with autism. Child Dev. 2000 Mar-Apr; 71(2): 447-56. (not available)	
	10	Bayliss WM and Starling EH (1902) The mechanism of pancreatic secretion. J Physiol (Lond) 28, 325-353	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/799,941		
		Filing Date	03/11/2004		
		First Named Inventor	Martha G. Welch		
		Art Unit	1615		
		Examiner Name			
Sheet	2	of	11	Attorney Docket Number	5199-134

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	Bitton A, Sewitch MJ, Peppercorn MA, deB Edwardes MD, Shah S, Ransil B, Locke SE. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol. 2003 Oct;98(10):2203-8	
	12	Blair HT, Schafe GE, Bauer EP, Rodrigues SM, LeDoux JE. Synaptic plasticity in the lateral amygdala: a cellular hypothesis of fear conditioning. Learn Mem. 2001 Sep-Oct;8(5):2	
	13	Bregonzio C, Armando I, Ando H, Jezova M, Baiardi G, Saavedra JM. (2003) Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am J Physiol Gastrointest Liver Physiol. .2003 Aug;285(2):G414-23	
	14	Breiner J, Beck S. (1984) Parents as change agents in the management of their developmentally delayed children's noncompliant behaviors: a critical review. Appl Res Ment Retard.;5(2):259-78. - (not available)	
	15	Buchsbaum MS, Hollander E, Haznedar MM, Tang C, Spiegel-Cohen J, Wei TC, Solimando A, Buchsbaum BR, Robins D, Bienstock C, Cartwright C, Mosovich S. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol. 2001 Jun; 4(2): 119-25. - (not available)	
	16	Chariton CG, Miller RL, Crawley JN, Handelsmann GE, O'Donohue TL. Secretin modulation of behavioral and physiological functions in the rat. Peptides. 1983 Sep-Oct;4(5):739-42	
	17	Charlton CG, O'Donohue TL, Miller RL, Jacobowitz DM. Secretin immunoreactivity in rat and pig brain. Peptides. 1981;2 Suppl 1:45-9	
	18	Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T, da Silva EA, Chugani HT. Altered serotonin synthesis in the dentatohalamocortical pathway in autistic boys. Ann Neurol. 1997 Oct;42(4):666-9	
	19	Chugani DC, Sundram BS, Behen M, Lee ML, Moore GJ. (1999) Evidence of altered energy metabolism in autistic children. Prog Neuropsychopharmacol Biol Psychiatry. May;23(4):635-41	
	20	Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol. 1999 Jun; 14(6): 388-94	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/799,941
		Filing Date	03/11/2004
		First Named Inventor	Martha G. Welch
		Art Unit	1615
Examiner Name			
Sheet 3	of 11	Attorney Docket Number	5199-134

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	21	Cook EH. Autism: review of neurochemical investigation. Synapse. 1990; 6(3): 292-308	
	22	Cushing BS, Yamamoto Y, Hoffman GE, Carter CS. Central expression of c-Fos in neonatal male and female prairie voles in response to treatment with oxytocin. Brain Res Dev Brain Res. 2003 Jul 12; 143(2): 129-36	
	23	Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci. 2001 Mar;933:222-34	
	24	Delgado M, Leceta J, Sun W, Gomariz RP, Ganea D. VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression. Ann N Y Acad Sci. 2000; 921: 68-78	
	25	Dohi T, Fujihashi K, Rennert PD, Iwatani K, Kiyono H, McGhee JR. Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses. J Exp Med. 1999 Apr 19; 189(8): 11 169-80	
	26	Drossman DA, Ringel Y, Vogt BA, Leserman J, Lin W, Smith JK, Whitehead W. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology. 2003 Mar;124(3):754-61	
	27	Eskandari F, Webster JI, Stenberg EM. Neural immune pathways and their connection to inflammatory diseases Arthritis Res Ther. 2003;5(6):251-65. – (not available – License restriction)	
	28	Farmer MA, Sundberg JP, Bristol IJ, Churchill GA, Li R, Elson CO, Leiter EH. A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24): 13820-5. Epub 2001 Nov 13	
	29	Farrell RJ. Epidermal growth factor for ulcerative colitis. N Engl J Med. 2003 Jul 24;349(4):395-7	
	30	Francis DD, Diorio J, Plotsky PM, Meaney MJ. Environmental enrichment reverses the effects of maternal separation on stress reactivity. J Neurosci. 2002 Sep 15;22(18):7840-3	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/799,941		
		Filing Date	03/11/2004		
		First Named Inventor	Martha G. Welch		
		Art Unit	1615		
		Examiner Name			
Sheet	4	of	11	Attorney Docket Number	5199-134

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	31	Francis DD, Young LJ, Meaney MJ, Insel TR. Naturally occurring differences in maternal care are associated with the expression of oxytocin and vasopressin (Vla) receptors: gender differences. J Neuroendocrinol. 2002 May; 14(5): 34	
	32	Friebe-Hoffmann U, Chiao JP, Rauk PN. Effect of IL-1beta and IL-6 on oxytocin secretion in human uterine smooth muscle cells. Am J Reprod Immunol. 2001 Sep; 46(3): 226-3 1. – (not available)	
	33	Gandhi S, Tsueshita T, Onyuksel H, Chandiwalla R, Rubinstein I. (2002) Interactions of human secretin with sterically stabilized phospholipid micelles amplify peptide-induced vasodilation in vivo. Peptides. ug;23(8):1433-9	
	34	Gassull MA. Nutrition and inflammatory bowel disease: its relation to pathophysiology, outcome and therapy. Dig Dis. 2003; 21(3): 220-7.	
	35	Gershon MD and D'Autreaux F. Personal communication 2003 – (not available)	
	36	Gershon MD. (1998) The Second Brain: a groundbreaking new understanding of nervous disorders of the stomach and intestine. New York: Harper Collins.p.163. – (not available)	
	37	Guilloteau P, Chayvialle JA, Toullec R, Grongnet JF, Bernard C. Early-life patterns of plasma gut regulatory peptide levels in calves: effects of the first meals. Biol Neonate. 1992;61(2):103-9.	
	38	Gupta S, Aggarwal S, Rashanravan B, Lee T. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. JNeuroimmunol. 1998 May 1; 85(1): 106-9.	
	39	Guth PH, Smith E. The effect of gastrointestinal hormones on the gastric microcirculation. Gastroenterology. 1976 Sep;71(3):435-8	
	40	Gutkowska J, Jankowski M, Mukaddam-Daher S, McCann SM. Oxytocin is a cardiovascular hormone. Braz J Med Biol Res. 2000 Jun;33(6):625-33	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/799,941		
		Filing Date	03/11/2004		
		First Named Inventor	Martha G. Welch		
		Art Unit	1615		
		Examiner Name			
Sheet	5	of	11	Attorney Docket Number	5199-134

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	41	Hart A, Kamm MA. Review article: mechanisms of initiation and perpetuation of gut inflammation by stress. Aliment Pharmacol Ther. 2002 Dec; 16(12):2017-28	
	42	Haznedar MM, Buchsbaum MS, Wei TC, Hof PR, Cartwright C, Bienstock CA, Hollander E. (2000) Limbic circuitry in patients with autism spectrum disorders studied with positron emission tomography and magnetic resonance imaging. Am J Psychiatry. Dec; 157	
	43	Helou CM, Imbert-Teboul M, Doucet A, Rajerison R, Chollet C, Alhenc-Gelas F, Marchetti J. (2003) Angiotensin receptor subtypes in thin and muscular juxtamedullary efferent arterioles of rat kidney. Am J Physiol Renal Physiol. Sep;285(3):F507-14	
	44	Higa KT, Mori E, Viana FF, Morris M, Michelini LC. Baroreflex control of heart rate by oxytocin in the solitary-vagal complex. Am J Physiol Regul Integr Comp Physiol. 2002 Feb;282(2):R537-45	
	45	Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S. (2003) Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology. Jan;28(1):193-8	
	46	Horvath K, Papadimitriou JC, Rabsztyrn A, Drachenberg C, Tildon JT. (1999) Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. Nov; 135(5):559-63	
	47	Horvath K, Penman JA. (2002) Autism and gastrointestinal symptoms. Curr Gastroenterol Rep. Jun;4(3):251-8. – (not available)	
	48	Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. (1998) Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys.; 9(1): 9-15	
	49	Iijima H, Takahashi I, Kishi D, Kim JK, Kawano S, Hori M, Kiyono H. (1999) Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. J Exp Med. Sep 6; 190(5): 607-15.	
	50	Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46(2):76-84	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/799,941
		Filing Date	03/11/2004
		First Named Inventor	Martha G. Welch
		Art Unit	1615
		Examiner Name	
Sheet	6	of	11
		Attorney Docket Number	5199-134

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	51	Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate an adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol. 2001 Nov 1;120(1-2):170-9	
	52	Konturek SJ, Zabielski R, Konturek JW, Czarnecki J. Neuroendocrinology of the pancreas; role of brain-gut axis in pancreatic secretion. Eur J Pharmacol. 2003 Nov 14;481(1):1-14	
	53	Kucharzik T, Luger N, Adolf M, Domschke W, Stoll R. Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease. Dig Dis Sci. 1997 Apr; 42(4): 805-12	
	54	Leong DS, Terron JA, Falcon-Neri A, Armando I, Ito T, Johren O, Tonelli LH, Hoe KL, Saavedra JM. (2002) Restraint stress modulates brain, pituitary and adrenal expression of angiotensin II AT(1A), AT(1B) and AT(2) receptors. Neuroendocrinology. Apr;75(4):227-40	
	55	Leventhal BL, Cook EH Jr, Morford M, Ravitz A, Freedman DX. Relationships of whole blood serotonin and plasma norepinephrine within families. J Autism Dev Disord. 1990 Dec; 20(4): 499-511. - (not available)	
	56	Levitt JG, O'Neill J, Blanton RE, Smalley S, Fadale D, McCracken JT, Guthrie D, Toga AW, Alger JR. Proton magnetic resonance spectroscopic imaging of the brain in childhood autism. Biol Psychiatry. 2003 Dec 15;54(12):1355-66	
	57	Lightdale JR, Siegal B, Heyman MB. Gastrointestinal symptoms in autistic children. Clin Perspec Gastroenterol 156-58, 2001. - (not available)	
	58	Linthorst AC, Reul JM. Brain neurotransmission during peripheral inflammation. Ann N Y Acad Sci. 1998 May 1;840:139-52	
	59	Luna B, Minshew NJ, Garver KE, Lazar NA, Thulborn KR, Eddy WF, Sweeney JA. Neocortical system abnormalities in autism: an fMRI study of spatial working memory. Neurology. 2002 Sep 24;59(6):834-40	
	60	Lupoli B, Johansson B, Uvnas-Moberg K, Svennersten-Sjaunja K. Effect of suckling on the release of oxytocin, prolactin, cortisol, gastrin, cholecystokinin, somatostatin and insulin in dairy cows and their calves. J Dairy Res. 2001 May;68(2):175-87. - (not available)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/799,941
		Filing Date	03/11/2004
		First Named Inventor	Martha G. Welch
		Art Unit	1615
Examiner Name			
Sheet 7		of 11	Attorney Docket Number 5199-134

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	61	Mack SO, Kc P, Wu M, Coleman BR, Tolentino-Silva FP, Haxhiu MA. Paraventricular oxytocin neurons are involved in neural modulation of breathing. J Appl Physiol. 2002 Feb;92(2):826-34	
	62	Malek-Ahmadi P. Cytokines and etiopathogenesis of pervasive developmental disorders. Med Hypotheses. 2001 Mar;56(3):321-4	
	63	Manfredini R, Tenedini E, Siena M, Tagliafico E, Montanari M, Grande A, Zanocco-Marani T, Poligani C, Zini R, Gemelli C, Bergamaschi A, Vignudelli T, De Rienzo F, De Benedetti PG, Menziani MC, Ferrari S. Development of an IL-6 antagonist peptide that induces apoptosis in 7TDI cells	
	64	Matthiesen AS, Ransjo-Arvidson AB, Nissen E, Uvnas-Moberg K. Postpartum maternal oxytocin release by newborns: effects of infant hand massage and sucking. Birth. 2001 Mar;28(1):13-9	
	65	McEwen BS. Early life influences on life-long patterns of behavior and health. Merit Retard Dev Disabil Res Rev. 2003;9(3):149-54. – (not available)	
	66	McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 2000 Dec 15;886(1-2):172-189	
	67	Meaney MJ, Aitken DH, van Berkel C, Bhatnagar S, Sapolsky RM. Effect of neonatal handling on age-related impairments associated with the hippocampus. Science. 1988 Feb 12;239(4841 Pt 1):766-8	
	68	Micheline LC, Marcelo MC, Amico J, Morris M. Oxytocinergic regulation of cardiovascular function: studies in oxytocin-deficient mice. Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H2269-76	
	69	Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, Hansen RL, Phillips TM. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol. 2001 May; 49(5): 597-606	
	70	Palecek J, Willis WD. The dorsal column pathway facilitates visceromotor responses to colorectal distention after colon inflammation in rats. Pain. 2003 Aug;104(3):501-7.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/799,941		
		Filing Date	03/11/2004		
		First Named Inventor	Martha G. Welch		
		Art Unit	1615		
		Examiner Name			
Sheet	8	of	11	Attorney Docket Number	5199-134

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	71	Palmer GC. Neurochemical coupled actions of transmitters in the microvasculature of the brain. Neurosci Biobehav Rev. 1986 Summer; 10(2):79-101	
	72	Paxinos, G., Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press. San Diego	
	73	Pedersen CA., Boccia ML. Oxytocin links mothering received, mothering bestowed and adult stress responses. Stress. 2002 Dec; 5(4): 259-67. – (not available – License restricted)	
	74	Penny WJ, Mayberry JF, Aggett PJ, Gilbert JO, Newcombe RG, Rhodes J. Relationship between trace elements, sugar consumption, and taste in Crohn's disease. Gut. 1983 Apr;24(4):288-92	
	75	Peterson G, Mason GA, Barakat AS, Pedersen CA. Oxytocin selectively increases holding and licking of neonates in preweanling but not postweanling juvenile rats. Behav Neurosci. 1991 Jun; 105(3): 470-7	
	76	Popovic M, Popovic N, Eric-Jovicic M, Jovanova-Nesic K. Immune Responses in Nucleus Basalis Magnocellularis-Lesioned Rats Exposed to Chronic Isolation Stress. Int J Neurosci. 1999 Jan; 100(1-4): 125131. – (not available – License restricted)	
	77	Porter RH, Winberg J. Unique salience of maternal breast odors for newborn infants. Neurosci Biobehav Rev. 1999;23(3):439-49.	
	78	Porter RH. Olfaction and human kin recognition. Genetica. 1998-99;104(3):259-63. – (not available – License restricted)	
	79	Rominger JM, Chey WY, Chang TM. Plasma secretin concentrations and gastric pH in healthy subjects and patients with digestive diseases. Dig Dis Sci. 1981 Jul; 26(7): 591-7	
	80	Rumsey JM, Ernst M. Functional neuroimaging of autistic disorders. Merit Retard Dev Disabil Res Rev. 2000; 6(3): 171-9. – (not available – License restricted)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/799,941		
		Filing Date	03/11/2004		
		First Named Inventor	Martha G. Welch		
		Art Unit	1615		
Examiner Name					
Sheet	9	of	11	Attorney Docket Number	5199-134

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	81	Saitoh O, Courchesne E, Egaas B, Lincoln AJ, Schreibman L. Cross-sectional area of the posterior hippocampus in autistic patients with cerebellar and corpus callosum abnormalities. Neurology. 1995 Feb; 45(2): 317-24	
	82	Saitoh O, Karns CM, Courchesne E. Development of the hippocampal formation from 2 to 42 years: MRI evidence of smaller area dentata in autism. Brain. 2001 Jul; 124(Pt 7): 1317-24	
	83	Sica AL, Greenberg HE, Scharf SM, Ruggiero DA. Chronic-intermittent hypoxia induces immediate early gene expression in the midline thalamus and epithalamus. Brain Res. 2000 Nov 17;883(2):224-8	
	84	Sidman R.L., Angevine J.B., Jr., Pierce E.T., (1971) Atlas of the Mouse Brain and Spinal Cord. Harvard University Press. Cambridge	
	85	Siegel BV Jr, Asarnow R, Tanguay P, Call JD, Abel L, Ho A, Lott I, Buchsbaum MS. Regional cerebral glucose metabolism and attention in adults with a history of childhood autism. J Neuropsychiatry Clin Neurosci. 1992 Fall; 4(4): 406-14	
	86	Spencer DM, Veldman GM, Banerjee S, Willis J, Levine AD. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology. 2002 Jan; 122(1): 94-105	
	87	Swanson LW.(2003) Brain Maps:Structure of the Rat Brain. Second Edition. Elsevier. Amsterdam. (not available)	
	88	Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougale CJ. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics. 2003 Nov; 112(5): e420	
	89	Tache Y, Garrick T, Raybould H. Central nervous system action of peptides to influence gastrointestinal motor function. Gastroenterology. 1990 Feb;98(2):517-28	
	90	Torrente F, Ashwood P, Day R, Machado N, Furlano RI, Anthony A, Davies SE, Wakefield AJ, Thomson MA, Walker-Smith JA, Murch SH. (2002) Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry;7(4):375-82. 334	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/799,941
		Filing Date	03/11/2004
		First Named Inventor	Martha G. Welch
		Art Unit	1615
Examiner Name			
Sheet 10 of 11	Attorney Docket Number 5199-134		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	91	Traub RJ, Silva E, Gebhart GF, Solodkin A. Noxious colorectal distention induced-c-Fos protein in limbic brain structures in the rat. Neurosci Lett. 1996 Sep 13;215(3):165-8	
	92	Uno H, Tarara R, Else JG, Suleman MA, Sapolsky RM. (1989) Hippocampal damage associated with prolonged and fatal stress in primates. J Neurosci. May;9(5):1705-11	
	93	Uvnas-Moberg K. Oxytocin linked antistress effects--the relaxation and growth response. Acta Physiol Scand Suppl. 1997;640:38-42.	
	94	Walker JK, Premont RT, Barak LS, Caron MG, Shetzline MA. (1999) Properties of secretin receptor internalization differ from those of the beta(2)-adrenergic receptor. J Biol Chem. Oct 29;274(44):31515-23	
	95	Warren RP, Odell JD, Warren WL, Burger RA, Maciulis A, Daniels WW, Torres AR. (1997) Brief report: immunoglobulin A deficiency in a subset of autistic subjects. J Autism Dev Disord. Apr;27(2):187-92. – (not available – License restricted)	
	96	Welch MG, Chaput P. Mother-child holding therapy and autism. Pa Med. 1988 Oct;91(10):33-8	
	97	Welch MG, Holding Time. New York: Simon and Schuster, 1988. – (not available)	
	98	Welch MG, Keune JD, Welch-Horan TB, Anwar N, Anwar M, Ruggiero DA. Secretin activates visceral brain regions in the rat including areas abnormal in autism. Cell Mol Neurobiol. 2003 Oct; 23(4-5): 817-37	
	99	Welch MG, Welch-Horan TB, Keune JD, Anwar N, Anwar M, Ludwig RJ, Ruggiero DA. Secretin: hypothalamic distribution and hypothesized neuroregulatory role in autism. Cell Mol Neurobiol. 2004 Apr; 24(2): 167-89. – (not available)	
	100	Welch MG, Welch-Horan TB, Keune JD, Ludwig RJ, Austin CL, Jacobson JS. Outcomes of an intervention to reinstate maternal nurturing among children with behavioral disorders. In prep. – (not available)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/799,941		
		Filing Date	03/11/2004		
		First Named Inventor	Martha G. Welch		
		Art Unit	1615		
		Examiner Name			
Sheet	11	of	11	Attorney Docket Number	5199-134

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	101	Welch MG, Welsh-Horan TB, Keune JD, Anwar N, Anwar M, Ludwig RG, Ruggiero DA (2003b) Neurohormonal Resolution of Genetic and Acquired IBD and Secondary Brain Activation in Areas Abnormal in Autism. Neurosci Abstracts: 33rd Annual Meeting Nov 8-12 – (not available)	
	102	Welch MG. (1983b) Retrieval from autism through mother-child holding therapy. In Call JD, Galenson E, Tyson RL, eds. Frontiers of Infant Psychiatry. 1983b New York: Basic Books	
	103	Welch MG. (1989) Holding Time: How When Why. Proceedings of the First International Congress of Holding Therapy. Regensburg, Germany. – (not available)	
	104	Welch MG. Appendix I: retrieval from autism through mother-child holding therapy In Tinbergen N and Tinbergen EA, 'Autistic' Children: New Hope for a Cure. George Allen & Unwin. London 1983a. 322-336	
	105	Welch MG. Toward prevention of developmental disorders. Pa Med. 1987 Mar;90(3):47-52	
	106	Welch, M.G. (1983a) Retrieval from autism through mother-child holding. In Tinbergen N and EA. Autistic Children - New Hope for a Cure. London and Boston: George, Allen and Unwin	
	107	White JF. (2003) Intestinal pathophysiology in autism. Exp Biol Med (Maywood). Jun;228(6):639-49	
	108	Yaniv D, Schafe GE, LeDoux JE, Richter-Levin G. A gradient of plasticity in the amygdala revealed by cortical and subcortical stimulation, in vivo. Neuroscience. 2001;106(3):613-20	
	109	Yaraee R, Ehtekar M, Ahmadiani A, Sabahi F. Neuropeptides (SP and CGRP) augment pro-inflammatory cytokine production in HSV-infected macrophages. Int Immunopharmacol. 2003 Dec; 3(13-14): 1883-7	
	110	Yirmiya N, Pilowsky T, Nemanov L, Arbelle S, Feinsilver T, Fried I, Ebstein RP. Evidence for an association with the serotonin transporter promoter region polymorphism and autism. Am J Med Genet. 2001 May 8; 105(4): 381	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.